These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
541 related items for PubMed ID: 26667069
1. Safety of mTOR inhibitors in adult solid organ transplantation. Ventura-Aguiar P, Campistol JM, Diekmann F. Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069 [Abstract] [Full Text] [Related]
8. A drug safety evaluation of everolimus in kidney transplantation. Holdaas H, Midtvedt K, Åsberg A. Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349 [Abstract] [Full Text] [Related]
9. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Diekmann F, Andrés A, Oppenheimer F. Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729 [Abstract] [Full Text] [Related]
10. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Holdaas H, Potena L, Saliba F. Transplant Rev (Orlando); 2015 Apr; 29(2):93-102. PubMed ID: 25227328 [Abstract] [Full Text] [Related]
11. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Perbos E, Juinier E, Guidicelli G, Dromer C, Merville P, Billes MA, Taupin JL, Neau-Cransac M. Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585 [Abstract] [Full Text] [Related]
12. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation. Fine NM, Kushwaha SS. Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747 [Abstract] [Full Text] [Related]
13. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M. Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607 [Abstract] [Full Text] [Related]
14. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Gonzalez-Vilchez F, Vazquez de Prada JA, Paniagua MJ, Gomez-Bueno M, Arizon JM, Almenar L, Roig E, Delgado J, Lambert JL, Perez-Villa F, Sanz-Julve ML, Crespo-Leiro M, Segovia J, Lopez-Granados A, Martinez-Dolz L, Mirabet S, Escribano P, Diaz-Molina B, Farrero M, Blasco T. Int J Cardiol; 2014 Jan 15; 171(1):15-23. PubMed ID: 24309084 [Abstract] [Full Text] [Related]
15. Use of sirolimus in solid organ transplantation. Augustine JJ, Bodziak KA, Hricik DE. Drugs; 2007 Jan 15; 67(3):369-91. PubMed ID: 17335296 [Abstract] [Full Text] [Related]
17. Everolimus in clinical practice in long-term liver transplantation: an observational study. Casanovas T, Argudo A, Peña-Cala MC. Transplant Proc; 2011 Jan 15; 43(6):2216-9. PubMed ID: 21839237 [Abstract] [Full Text] [Related]
18. mTOR Inhibition and Clinical Transplantation: Liver. Nashan B. Transplantation; 2018 Feb 15; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639 [Abstract] [Full Text] [Related]
19. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. Ganschow R, Pape L, Sturm E, Bauer J, Melter M, Gerner P, Höcker B, Ahlenstiel T, Kemper M, Brinkert F, Sachse MM, Tönshoff B. Pediatr Transplant; 2013 Nov 15; 17(7):694-706. PubMed ID: 24004351 [Abstract] [Full Text] [Related]